Oncology Institute Financials
TOI Stock | USD 1.00 0.04 4.17% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 1.98 | 1.89 |
|
| |||||
Current Ratio | 2.61 | 3.71 |
|
|
The essential information of the day-to-day investment outlook for Oncology Institute includes many different criteria found on its balance sheet. An individual investor should monitor Oncology Institute's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Oncology Institute.
Net Income |
|
Oncology | Select Account or Indicator |
Oncology Institute Stock Summary
Oncology Institute competes with Ramsay Health, Medical Facilities, Fresenius, Lifestance Health, and Agilon Health. The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California. Oncology Institute operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange. It employs 658 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US68236X1000 |
CUSIP | 68236X100 23343Q100 |
Location | California; U.S.A |
Business Address | 18000 Studebaker Road, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | theoncologyinstitute.com |
Phone | 562 735 3226 |
Currency | USD - US Dollar |
Oncology Institute Key Financial Ratios
Return On Equity | -1.61 | ||||
Profit Margin | (0.19) % | ||||
Operating Margin | (0.14) % | ||||
Price To Sales | 0.19 X | ||||
Revenue | 324.24 M |
Oncology Institute Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 65.7M | 203.4M | 263.7M | 209.2M | 240.6M | 176.4M | |
Other Current Liab | 6.1M | 13.3M | 13.3M | 13.5M | 15.5M | 11.2M | |
Net Debt | 5.9M | (114.1M) | 94.2M | 86.2M | 99.1M | 104.1M | |
Retained Earnings | (52.3M) | (63.2M) | (61.6M) | (146.2M) | (131.5M) | (125.0M) | |
Accounts Payable | 12.6M | 15.6M | 9.4M | 14.4M | 16.6M | 13.4M | |
Cash | 6.0M | 114.3M | 14.0M | 33.5M | 38.5M | 37.5M | |
Net Receivables | 17.3M | 21.2M | 40.4M | 42.9M | 49.3M | 30.0M | |
Good Will | 14.2M | 26.6M | 23.4M | 7.2M | 6.5M | 6.2M | |
Inventory | 4.4M | 6.4M | 9.3M | 13.7M | 15.7M | 8.3M | |
Other Current Assets | 2.1M | 12.1M | 6.9M | 4.0M | 4.7M | 5.7M | |
Total Liab | 37.6M | 99.3M | 139.1M | 152.2M | 175.0M | 98.0M | |
Net Invested Capital | (40.1M) | 104.3M | 203.8M | 143.9M | 165.4M | 89.3M | |
Total Current Assets | 29.7M | 154.1M | 130.5M | 143.5M | 165.0M | 105.5M | |
Net Working Capital | 1.1M | 124.3M | 100.7M | 108.7M | 125.0M | 75.5M | |
Intangible Assets | 19.5M | 18.2M | 18.0M | 17.9M | 16.1M | 15.3M |
Oncology Institute Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Tax Provision | (492.8K) | (671K) | (243K) | (89K) | (80.1K) | (76.1K) | |
Net Interest Income | (347.1K) | (320K) | (4.1M) | (7.3M) | (6.6M) | (6.2M) | |
Interest Expense | 347.1K | 320K | 4.1M | 6.8M | 7.8M | 8.2M | |
Total Revenue | 187.5M | 203.0M | 252.5M | 324.2M | 372.9M | 226.6M | |
Gross Profit | 36.9M | 40.8M | 52.1M | 59.6M | 68.5M | 45.0M | |
Operating Income | (8.2M) | (45.9M) | (72.0M) | (77.0M) | (69.3M) | (65.9M) | |
Ebit | (14.5M) | (11.3M) | 4.0M | (76.3M) | (68.7M) | (65.3M) | |
Ebitda | (11.3M) | (7.9M) | 8.4M | (70.5M) | (63.4M) | (60.2M) | |
Cost Of Revenue | 150.6M | 162.2M | 200.4M | 264.7M | 304.4M | 181.5M | |
Income Before Tax | (14.8M) | (11.6M) | 1.9M | (83.1M) | (74.8M) | (71.1M) | |
Net Income | (14.3M) | (10.9M) | 1.7M | (83.1M) | (74.8M) | (71.0M) | |
Income Tax Expense | (492.8K) | (671K) | 247K | (36K) | (32.4K) | (30.8K) |
Oncology Institute Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | (465.2K) | (1.8M) | (1.7M) | (4.4M) | (3.9M) | (3.7M) | |
Investments | (8.8M) | (12.2M) | (117.5M) | 18.4M | 16.6M | 17.4M | |
Change In Cash | 3.6M | 109.2M | (101.2M) | 19.5M | 17.5M | 18.4M | |
Free Cash Flow | (685.9K) | (35.7M) | (67.3M) | (40.9M) | (36.8M) | (35.0M) | |
Depreciation | 3.2M | 3.3M | 4.4M | 5.9M | 6.8M | 3.8M | |
Other Non Cash Items | 11.9M | (33.9M) | (75.2M) | 20.8M | 18.7M | 19.6M | |
Capital Expenditures | 1.2M | 3.0M | 5.5M | 4.6M | 5.3M | 3.0M | |
Net Income | (14.3M) | (10.9M) | 1.7M | (83.1M) | (74.8M) | (71.0M) | |
End Period Cash Flow | 6.0M | 115.2M | 14.0M | 33.5M | 38.5M | 31.4M | |
Change To Netincome | 1.2M | 10.6M | 7.6M | (47.2M) | (42.5M) | (40.4M) |
Oncology Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oncology Institute's current stock value. Our valuation model uses many indicators to compare Oncology Institute value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncology Institute competition to find correlations between indicators driving Oncology Institute's intrinsic value. More Info.Oncology Institute is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Oncology Institute's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oncology Institute's earnings, one of the primary drivers of an investment's value.Oncology Institute Systematic Risk
Oncology Institute's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Oncology Institute volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Oncology Institute correlated with the market. If Beta is less than 0 Oncology Institute generally moves in the opposite direction as compared to the market. If Oncology Institute Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Oncology Institute is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Oncology Institute is generally in the same direction as the market. If Beta > 1 Oncology Institute moves generally in the same direction as, but more than the movement of the benchmark.
Oncology Institute Thematic Clasifications
Oncology Institute is part of Healthcare investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Healthcare industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Healthcare | View |
Today, most investors in Oncology Institute Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Oncology Institute's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Oncology Institute growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Oncology Institute March 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Oncology Institute help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Oncology Institute. We use our internally-developed statistical techniques to arrive at the intrinsic value of Oncology Institute based on widely used predictive technical indicators. In general, we focus on analyzing Oncology Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Oncology Institute's daily price indicators and compare them against related drivers.
Downside Deviation | 7.06 | |||
Information Ratio | 0.2814 | |||
Maximum Drawdown | 38.02 | |||
Value At Risk | (8.00) | |||
Potential Upside | 20.24 |
Complementary Tools for Oncology Stock analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |